Literature DB >> 14690191

Biphasic response to dobutamine predicts improvement of left ventricular dysfunction after revascularization: correlation with positron emission and rest-redistribution 201Tl tomographies.

M Hernandez-Pampaloni1, V Peral, J L Carreras, L Sanchez-Harguindey, I Vilacosta.   

Abstract

BACKGROUND: Dobutamine echocardiography (DSE), positron emission tomography (PET) and 201Tl-single photon emission computed tomography (SPECT) have been used to identify myocardial viability. There are few reports, however, that compare high doses DSE with myocardial metabolic and perfusion imaging techniques in the same patient population. The aim of this study was to determine the correlation between high doses DSE, metabolic PET and 201Tl-SPECT imaging to predict the recovery of function after revascularization in patients with severe left ventricular (LV) dysfunction.
METHODS: Twenty-five patients underwent DSE (up to 40 microg/kg/min), rest and 4-hour redistribution 201Tl SPECT, rest 13N-ammonia and 18fluoro-deoxy-glucose PET imaging and coronary angiography 7-10 days before surgical revascularization. A follow-up 2D-echocardiography was performed 6 weeks after surgery.
RESULTS: Of the 109 successfully revascularized segments with severe dysfunction, 62 (57%) improved. LV ejection fraction increased from 30 +/- 10% to 42 +/- 13 at follow-up (p < 0.05). 201Tl SPECT, PET and the presence of contractile reserve determined by DSE had a similar sensitivity (77-87%) to predict recovery of function, but specificity was higher for the PET mismatch pattern and biphasic DSE (85-89%) than for any of the 201Tl viability patterns (19-64%). The highest positive predictive values were obtained by biphasic DSE and PET mismatch pattern (78-79%) compared to all other criteria (54-67%). In a multivariate model, which included evidence of viability by all imaging modalities, biphasic response was the best predictor of regional recovery of function (Odds ratio, OR: 9.9, 95% confidence intervals, 95% CI: 3.5-27.8).
CONCLUSIONS: Although DSE and PET had overall comparable results, the presence of contractile reserve by the biphasic response to dobutamine was a best predictor for the improvement of LV contractile function in this group of patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14690191     DOI: 10.1023/b:caim.0000004302.68305.80

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  25 in total

1.  Prediction of global left ventricular function after bypass surgery in patients with severe left ventricular dysfunction. Impact of pre-operative myocardial function, perfusion, and metabolism.

Authors:  A Pasquet; M S Lauer; M J Williams; M A Secknus; B Lytle; T H Marwick
Journal:  Eur Heart J       Date:  2000-01       Impact factor: 29.983

2.  Rest-injected thallium-201 imaging for assessing viability of severe asynergic regions.

Authors:  T Mori; K Minamiji; H Kurogane; K Ogawa; Y Yoshida
Journal:  J Nucl Med       Date:  1991-09       Impact factor: 10.057

3.  Assessment of myocardial viability by dobutamine echocardiography, positron emission tomography and thallium-201 SPECT: correlation with histopathology in explanted hearts.

Authors:  H Baumgartner; G Porenta; Y K Lau; M Wutte; U Klaar; M Mehrabi; R J Siegel; J Czernin; G Laufer; H Sochor; H Schelbert; M C Fishbein; G Maurer
Journal:  J Am Coll Cardiol       Date:  1998-11-15       Impact factor: 24.094

4.  Prediction of improvement of regional left ventricular function after surgical revascularization. A comparison of low-dose dobutamine echocardiography with 201Tl single-photon emission computed tomography.

Authors:  M Arnese; J H Cornel; A Salustri; A Maat; A Elhendy; A E Reijs; F J Ten Cate; D Keane; A H Balk; J R Roelandt
Journal:  Circulation       Date:  1995-06-01       Impact factor: 29.690

5.  Akinesis becoming dyskinesis during high-dose dobutamine stress echocardiography: a marker of myocardial ischemia or a mechanical phenomenon?

Authors:  M Arnese; P M Fioretti; J H Cornel; J Postma-Tjoa; A E Reijs; J R Roelandt
Journal:  Am J Cardiol       Date:  1994-05-01       Impact factor: 2.778

6.  Defects on SPECT "perfusion" images can occur due to abnormal segmental contraction.

Authors:  R L Eisner; L S Schmarkey; S E Martin; D Carey; M A Worthy; T H Chu; S F Horowitz; R E Patterson
Journal:  J Nucl Med       Date:  1994-04       Impact factor: 10.057

7.  Myocardial viability: fluorine-18-deoxyglucose positron emission tomography in prediction of wall motion recovery after revascularization.

Authors:  M J Knuuti; M Saraste; P Nuutila; R Härkönen; U Wegelius; A Haapanen; J Bergman; M Haaparanta; T Savunen; L M Voipio-Pulkki
Journal:  Am Heart J       Date:  1994-04       Impact factor: 4.749

8.  Assessment of myocardial viability in patients with chronic coronary artery disease. Rest-4-hour-24-hour 201Tl tomography versus dobutamine echocardiography.

Authors:  P Perrone-Filardi; L Pace; M Prastaro; F Squame; S Betocchi; A Soricelli; F Piscione; C Indolfi; T Crisci; M Salvatore; M Chiariello
Journal:  Circulation       Date:  1996-12-01       Impact factor: 29.690

9.  Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry.

Authors:  M Emond; M B Mock; K B Davis; L D Fisher; D R Holmes; B R Chaitman; G C Kaiser; E Alderman; T Killip
Journal:  Circulation       Date:  1994-12       Impact factor: 29.690

10.  Influence of subendocardial ischemia on transmural myocardial function.

Authors:  N C Edwards; A J Sinusas; J D Bergin; D D Watson; M Ruiz; G A Beller
Journal:  Am J Physiol       Date:  1992-02
View more
  2 in total

1.  Viability assessment: nuclear imaging vs. dobutamine echocardiography.

Authors:  Jeroen J Bax; Ernst E van der Wall
Journal:  Int J Cardiovasc Imaging       Date:  2003-12       Impact factor: 2.357

2.  Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-10-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.